View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 3, 2020updated 27 Oct 2021 11:42am

Aspen Pharmacare to manufacture Covid-19 vaccine candidate with J&J

Aspen’s South African subsidiary Aspen Pharmacare has signed a preliminary agreement with two Johnson & Johnson (J&J) subsidiaries for the technical transfer and proposed commercial manufacture of their Covid-19 vaccine candidate.

Aspen’s South African subsidiary Aspen Pharmacare has signed a preliminary agreement with two Johnson & Johnson (J&J) subsidiaries for the technical transfer and proposed commercial manufacture of their Covid-19 vaccine candidate.

At present, the investigational vaccine candidate, Ad26.COV2-S, is undergoing clinical trials.

Under the terms of the deal, signed with Janssen Pharmaceuticals and Janssen Pharmaceutica, Aspen Pharmacare will be responsible for the formulation, filling and secondary packaging of the vaccine for supply to J&J.

Aspen Group chief executive Stephen Saad said: “We have been selected as a vaccine partner by Johnson & Johnson and this project will receive priority focus.

“We are particularly pleased to be given the opportunity of providing assistance for patients in need across the world from our South African base.”

Manufacturing of Ad26.COV2-S will take place in Aspen Pharmacare’s existing sterile facility in Port Elizabeth, South Africa, developed with an investment of over R3bn ($1.85bn).

The facility is complete with high technology equipment and systems for making sterile drugs and vaccines, packaged into vials, ampoules and pre-filled syringes.

Aspen will also provide the necessary capacity required for the production.

The production area for manufacture has the capacity to produce over 300 million doses a year.

Furthermore, the facility obtained accreditation from international regulatory authorities and supplies lifesaving medicines to domestic and international markets.

The deal is subject to the successful completion of the relevant technology transfer activities and finalisation of certain terms related to commercial manufacturing.

Aspen is a global supplier for antiretrovirals for the treatment of HIV / AIDS, multi-drug-resistant-TB products and Covid-19-related treatments such as anaesthetics and dexamethasone.

In August, J&J unit Janssen Pharmaceutical signed an agreement with the US Government for the large scale domestic production and supply of 100 million doses of Ad26.COV2.S.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology